Literature DB >> 1744265

Effect of anticapsular antibodies on neutrophil phagocytosis of Staphylococcus aureus.

A J Guidry1, S P Oliver, K E Squiggins, E F Erbe, H H Dowlen, C N Hambleton, L M Berning.   

Abstract

One of the major virulence factors of Staphylococcus aureus is development of an exopolysaccharide capsule in vivo, which inhibits recognition of antibodies to highly antigenic cell wall by neutrophils. To circumvent this inhibition, an attempt was made to produce anticapsular antibodies. Three cows per group were immunized in midlactation by injections in the area of the supramammary lymph node and intramuscularly and were boosted on d 14, 42, and 70 with three variants of Smith S. aureus: compact, unencapsulated; diffuse, rigid capsule; and diffuse large clearing, exceptionally large flaccid capsule using dextran sulfate as adjuvant. Serum agglutination and ELISA titers of cows immunized with diffuse and diffuse large clearing increased after immunization and after each boost and remained elevated to the end of the experiment at 112 d. Phagocytosis of diffuse and diffuse large clearing, measured by flow cytometry, was enhanced by immunization with either organism. No antibody response to capsule or enhanced phagocytosis of diffuse developed in cows immunized with compact. However, anticompact antibodies were opsonic for diffuse large clearing. These data show that bovine antibodies to S. aureus capsule are opsonic for bovine neutrophils and that capsule plays a role in inhibition of cell-wall opsonization of S. aureus.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1744265     DOI: 10.3168/jds.S0022-0302(91)78525-1

Source DB:  PubMed          Journal:  J Dairy Sci        ISSN: 0022-0302            Impact factor:   4.034


  7 in total

1.  Staphylococcus aureus capsular polysaccharide types 5 and 8 reduce killing by bovine neutrophils in vitro.

Authors:  Annette H Kampen; Tore Tollersrud; Arve Lund
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

2.  Staphylococcus aureus agr genotypes with enterotoxin production capabilities can resist neutrophil bactericidal activity.

Authors:  I K Mullarky; C Su; N Frieze; Y H Park; L M Sordillo
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

Review 3.  Staphylococcus schweitzeri-An Emerging One Health Pathogen?

Authors:  Chantal Akoua-Koffi; Adèle Kacou N'Douba; Joseph Allico Djaman; Mathias Herrmann; Frieder Schaumburg; Silke Niemann
Journal:  Microorganisms       Date:  2022-04-02

4.  Survey of potential factors involved in the low frequency of CP5 and CP8 expression in Staphylococcus aureus isolates from mastitis of dairy cattle from Argentina, Chile, and Uruguay.

Authors:  Maria Belen Ambroggio; Melina Soledad Perrig; Cecilia Camussone; Nazarena Pujato; Alicia Bertón; Edgardo Gianneechini; Silvia Alvarez; Ivan Sergio Marcipar; Luis Fernando Calvinho; Maria Sol Barbagelata
Journal:  J Appl Genet       Date:  2018-05-03       Impact factor: 3.240

Review 5.  Chronic Rhinosinusitis, S. aureus Biofilm and Secreted Products, Inflammatory Responses, and Disease Severity.

Authors:  Gohar Shaghayegh; Clare Cooksley; Mahnaz Ramezanpour; Peter-John Wormald; Alkis James Psaltis; Sarah Vreugde
Journal:  Biomedicines       Date:  2022-06-09

6.  Genotypic and phenotypic detection of capsular polysaccharides in Staphylococcus aureus isolated from bovine intramammary infections in Argentina.

Authors:  C Camussone; P Rejf; N Pujato; A Schwab; I Marcipar; L F Calvinho
Journal:  Braz J Microbiol       Date:  2012-06-01       Impact factor: 2.476

7.  Molecular epidemiology and expression of capsular polysaccharides in Staphylococcus aureus clinical isolates in the United States.

Authors:  Naglaa Mohamed; Yekaterina Timofeyeva; Dorota Jamrozy; Eduardo Rojas; Li Hao; Natalie C Silmon de Monerri; Julio Hawkins; Guy Singh; Bing Cai; Paul Liberator; Shite Sebastian; Robert G K Donald; Ingrid L Scully; C Hal Jones; C Buddy Creech; Isaac Thomsen; Julian Parkhill; Sharon J Peacock; Kathrin U Jansen; Matthew T G Holden; Annaliesa S Anderson
Journal:  PLoS One       Date:  2019-01-14       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.